Emmanuel Kemboi - Profile on Academia.edu (original) (raw)

Celestine Ashimosi related author profile picture

Antonio Mazza related author profile picture

Jean Plum related author profile picture

A. Dagnra related author profile picture

Albert Kasembeli related author profile picture

L. Aleixo related author profile picture

Carol Metcalf related author profile picture

Anita Kuras related author profile picture

Souleymane SAWADOGO related author profile picture

Jonah Omooja related author profile picture

Uploads

Papers by Emmanuel Kemboi

Research paper thumbnail of HemaSpot, a Novel Blood Storage Device for HIV-1 Drug Resistance Testing

Journal of Clinical Microbiology, 2015

HemaSpot, a novel dried-blood storage filter device, was used for HIV-1 pol resistance testing in... more HemaSpot, a novel dried-blood storage filter device, was used for HIV-1 pol resistance testing in 30 fresh United States blood samples and 54 previously frozen Kenyan blood samples. Genotyping succeeded in 79% and 58% of samples, respectively, improved with shorter storage and higher viral load, and had good (86%) resistance mutation concordance to plasma.

Research paper thumbnail of Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya

Journal of the International AIDS Society, 2016

Tenofovir-based first-line antiretroviral therapy (ART) is recommended globally. To evaluate the ... more Tenofovir-based first-line antiretroviral therapy (ART) is recommended globally. To evaluate the impact of its incorporation into the World Health Organization (WHO) guidelines, we examined treatment failure and drug resistance among a cohort of patients on tenofovir-based first-line ART at the Academic Model Providing Access to Healthcare, a large HIV treatment programme in western Kenya. We determined viral load (VL), drug resistance and their correlates in patients on ≥six months of tenofovir-based first-line ART. Based on enrolled patients' characteristics, we described these measures in those with (prior ART group) and without (tenofovir-only group) prior non-tenofovir-based first-line ART using Wilcoxon rank sum and Fisher's exact tests. Among 333 participants (55% female; median age 41 years; median CD4 336 cells/µL), detectable (>40 copies/mL) VL was found in 18%, and VL>1000 copies/mL (WHO threshold) in 10%. Virologic failure at both thresholds was significant...

Research paper thumbnail of HemaSpot, a Novel Blood Storage Device for HIV-1 Drug Resistance Testing

Journal of Clinical Microbiology, 2015

HemaSpot, a novel dried-blood storage filter device, was used for HIV-1 pol resistance testing in... more HemaSpot, a novel dried-blood storage filter device, was used for HIV-1 pol resistance testing in 30 fresh United States blood samples and 54 previously frozen Kenyan blood samples. Genotyping succeeded in 79% and 58% of samples, respectively, improved with shorter storage and higher viral load, and had good (86%) resistance mutation concordance to plasma.

Research paper thumbnail of Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya

Journal of the International AIDS Society, 2016

Tenofovir-based first-line antiretroviral therapy (ART) is recommended globally. To evaluate the ... more Tenofovir-based first-line antiretroviral therapy (ART) is recommended globally. To evaluate the impact of its incorporation into the World Health Organization (WHO) guidelines, we examined treatment failure and drug resistance among a cohort of patients on tenofovir-based first-line ART at the Academic Model Providing Access to Healthcare, a large HIV treatment programme in western Kenya. We determined viral load (VL), drug resistance and their correlates in patients on ≥six months of tenofovir-based first-line ART. Based on enrolled patients' characteristics, we described these measures in those with (prior ART group) and without (tenofovir-only group) prior non-tenofovir-based first-line ART using Wilcoxon rank sum and Fisher's exact tests. Among 333 participants (55% female; median age 41 years; median CD4 336 cells/µL), detectable (>40 copies/mL) VL was found in 18%, and VL>1000 copies/mL (WHO threshold) in 10%. Virologic failure at both thresholds was significant...

Log In